Taiho Pharmaceutical Co., Ltd. - Product Pipeline Review

Global Markets Direct’s, ‘Taiho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016’, provides an overview of the Taiho Pharmaceutical Co., Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Taiho Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Taiho Pharmaceutical Co., Ltd.

The report provides overview of Taiho Pharmaceutical Co., Ltd. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Taiho Pharmaceutical Co., Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Taiho Pharmaceutical Co., Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Taiho Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Taiho Pharmaceutical Co., Ltd.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Taiho Pharmaceutical Co., Ltd.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Taiho Pharmaceutical Co., Ltd. Snapshot 6

Taiho Pharmaceutical Co., Ltd. ...

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Taiho Pharmaceutical Co., Ltd. Snapshot 6

Taiho Pharmaceutical Co., Ltd. Overview 6

Key Facts 6

Taiho Pharmaceutical Co., Ltd. - Research and Development Overview 7

Key Therapeutic Areas 7

Taiho Pharmaceutical Co., Ltd. - Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products - Monotherapy 12

Pipeline Products - Combination Treatment Modalities 13

Pipeline Products - Partnered Products 14

Partnered Products/Combination Treatment Modalities 15

Pipeline Products - Out-Licensed Products 16

Out-Licensed Products/Combination Treatment Modalities 17

Taiho Pharmaceutical Co., Ltd. - Pipeline Products Glance 18

Taiho Pharmaceutical Co., Ltd. - Late Stage Pipeline Products 18

Pre-Registration Products/Combination Treatment Modalities 18

Phase III Products/Combination Treatment Modalities 19

Taiho Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products 20

Phase II Products/Combination Treatment Modalities 20

Phase I Products/Combination Treatment Modalities 21

Taiho Pharmaceutical Co., Ltd. - Early Stage Pipeline Products 22

IND/CTA Filed Products/Combination Treatment Modalities 22

Preclinical Products/Combination Treatment Modalities 23

Taiho Pharmaceutical Co., Ltd. - Drug Profiles 24

(calcium folinate + gimeracil + oteracil + tegafur) - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

(gimeracil + oteracil + tegafur) - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

(tipiracil hydrochloride + trifluridine) - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

bilastine - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

netupitant - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

TAS-114 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

TAS-115 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

TAS-116 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

TAS-117 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

TAS-119 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

TAS-120 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

TAS-121 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

TAS-205 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

TAS-303 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

TAS-3681 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

TAS-5567 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

trabectedin - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Taiho Pharmaceutical Co., Ltd. - Pipeline Analysis 56

Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Target 56

Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration 58

Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type 59

Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action 60

Taiho Pharmaceutical Co., Ltd. - Dormant Projects 62

Taiho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products 63

Discontinued Pipeline Product Profiles 64

(gimeracil + oteracil + tegafur) 64

(tipiracil hydrochloride + trifluridine) 64

orantinib 64

suplatast tosilate 64

Taiho Pharmaceutical Co., Ltd. - Company Statement 65

Taiho Pharmaceutical Co., Ltd. - Locations And Subsidiaries 66

Head Office 66

Other Locations & Subsidiaries 66

Appendix 67

Methodology 67

Coverage 67

Secondary Research 67

Primary Research 67

Expert Panel Validation 67

Contact Us 67

Disclaimer 68

List of Tables

List of Tables

Taiho Pharmaceutical Co., Ltd., Key Facts 6

Taiho Pharmaceutical Co., Ltd. - Pipeline by Indication, 2016 9

Taiho Pharmaceutical Co., Ltd. - ...

List of Tables

Taiho Pharmaceutical Co., Ltd., Key Facts 6

Taiho Pharmaceutical Co., Ltd. - Pipeline by Indication, 2016 9

Taiho Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016 11

Taiho Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016 12

Taiho Pharmaceutical Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016 13

Taiho Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2016 14

Taiho Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2016 15

Taiho Pharmaceutical Co., Ltd. - Out-Licensed Products in Pipeline, 2016 16

Taiho Pharmaceutical Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2016 17

Taiho Pharmaceutical Co., Ltd. - Pre-Registration, 2016 18

Taiho Pharmaceutical Co., Ltd. - Phase III, 2016 19

Taiho Pharmaceutical Co., Ltd. - Phase II, 2016 20

Taiho Pharmaceutical Co., Ltd. - Phase I, 2016 21

Taiho Pharmaceutical Co., Ltd. - IND/CTA Filed, 2016 22

Taiho Pharmaceutical Co., Ltd. - Preclinical, 2016 23

Taiho Pharmaceutical Co., Ltd. - Pipeline by Target, 2016 57

Taiho Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016 58

Taiho Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016 59

Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2016 61

Taiho Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2016 62

Taiho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2016 63

Taiho Pharmaceutical Co., Ltd., Subsidiaries 66

List of Figures

List of Figures

Taiho Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2016 8

Taiho Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, ...

List of Figures

Taiho Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2016 8

Taiho Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016 11

Taiho Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016 12

Taiho Pharmaceutical Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016 13

Taiho Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2016 14

Taiho Pharmaceutical Co., Ltd. - Out-Licensed Products in Pipeline, 2016 16

Taiho Pharmaceutical Co., Ltd. - Pipeline by Top 10 Target, 2016 56

Taiho Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016 58

Taiho Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016 59

Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016 60

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports